These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 8292969

  • 1. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
    Holdsworth MT, Roon R, Ferguson J, Martinez L, Stidley CA, Neidhart JA.
    Biotechnol Ther; 1993; 4(3-4):183-95. PubMed ID: 8292969
    [Abstract] [Full Text] [Related]

  • 2. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
    Yau JC, Neidhart JA, Triozzi P, Verma S, Nemunaitis J, Quick DP, Mayernik DG, Oette DH, Haynes FA, Holcenberg J.
    Am J Hematol; 1996 Apr; 51(4):289-95. PubMed ID: 8602629
    [Abstract] [Full Text] [Related]

  • 3. Hematopoietic colony-stimulating factors. Uses in combination with standard chemotherapeutic regimens and in support of dose intensification.
    Neidhart JA.
    Cancer; 1992 Aug 15; 70(4 Suppl):913-20. PubMed ID: 1379115
    [Abstract] [Full Text] [Related]

  • 4. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
    Bernstein SH, Christiansen NP, Fay JP, Brown R, Herzig R, Frankel S, Blumenson L, Herzig GP.
    Exp Hematol; 1996 Oct 15; 24(12):1363-8. PubMed ID: 8913281
    [Abstract] [Full Text] [Related]

  • 5. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
    Shaffer DW, Smith LS, Burris HA, Clark GM, Eckardt JR, Fields SM, Weiss GR, Rinaldi DA, Bowen KJ, Kuhn JG.
    Cancer Res; 1993 Dec 15; 53(24):5929-33. PubMed ID: 8261405
    [Abstract] [Full Text] [Related]

  • 6. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF.
    Alvarado Ibarra ML, Borbolla Escoboza JR, López-Hernández MA, González-Avante CM, FloresChapa JD, Trueba Christy E, Anaya Cuellar I.
    Rev Invest Clin; 1999 Dec 15; 51(2):77-80. PubMed ID: 10410585
    [Abstract] [Full Text] [Related]

  • 7. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O, Foss B, Petersen H.
    Eur Cytokine Netw; 2001 Dec 15; 12(2):231-8. PubMed ID: 11399510
    [Abstract] [Full Text] [Related]

  • 8. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L.
    Ann Oncol; 1994 Oct 15; 5(8):709-16. PubMed ID: 7826903
    [Abstract] [Full Text] [Related]

  • 9. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
    Stewart DA, Guo D, Morris D, Poon MC, Ruether BA, Jones AR, Klassen J, Auer I, Luider J, Chaudhry A, Brown C, Russell JA.
    Bone Marrow Transplant; 1999 Jan 15; 23(2):111-7. PubMed ID: 10197794
    [Abstract] [Full Text] [Related]

  • 10. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep 15; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

  • 11. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF, Chan HO.
    Pharmacotherapy; 2005 Mar 15; 25(3):372-8. PubMed ID: 15843284
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia].
    Shi YK, Sun Y, Su M.
    Zhonghua Zhong Liu Za Zhi; 1994 Sep 15; 16(5):356-9. PubMed ID: 7895587
    [Abstract] [Full Text] [Related]

  • 14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun 15; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 15. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.
    Neidhart JA, Mangalik A, Stidley CA, Tebich SL, Sarmiento LE, Pfile JE, Oette DH, Oldham FB.
    J Clin Oncol; 1992 Sep 15; 10(9):1460-9. PubMed ID: 1517789
    [Abstract] [Full Text] [Related]

  • 16. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O, Kakehi Y, Arai Y, Tomoyoshi T, Okada Y, Matsuda T, Mikami O, Fukuyama T, Hida S, Okabe T.
    Int J Urol; 1995 Nov 15; 2(5):316-21. PubMed ID: 8749950
    [Abstract] [Full Text] [Related]

  • 17. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, Citarrella P.
    Haematologica; 1999 Nov 15; 84(11):1016-23. PubMed ID: 10553163
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
    Ford PA, Arbuck SG, Minniti C, Miller LL, DeMaria D, O'Dwyer PJ.
    Eur J Cancer; 1996 Apr 15; 32A(4):631-5. PubMed ID: 8695266
    [Abstract] [Full Text] [Related]

  • 19. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Färber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R.
    Bone Marrow Transplant; 1998 Oct 15; 22(7):625-30. PubMed ID: 9818688
    [Abstract] [Full Text] [Related]

  • 20. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS.
    J Clin Oncol; 1996 Nov 15; 14(11):2976-83. PubMed ID: 8918495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.